The Foundation Dedicated to Discovering a Cure for Neuroendocrine Cancer

Caring for Carcinoid Foundation

Past Symposium

2008 CFCF Research Symposium:

  • Date:  September 3-5, 2008
  • Location: Harvard Medical Center, Boston, MA
  • Scientific organizers: Arnold J. Levine, PhD & Evan Vosburgh, MD
  • Sponsoring organizations: Caring for Carcinoid Foundation and Raymond and Beverly Sackler Foundation
  • Program: Click here for Agenda and Participants

Results

Our 2008 CFCF Research Symposium validated our Research Action Plan and confirmed the most immediate research priorities:

 

2006 CFCF Research Symposium

  • Date:  December 2, 2006
  • Location:  Boston, MA
  • Participants: Leaders from the scientific community, the pharmaceutical industry, and the government participated in our 2006 CFCF Research Symposium:
    • Dr. Daniel Chung, Clinical Director of Gastrointestinal Cancer Genetics Program, Massachusetts General Hospital
    • Dr. Vikram Deshpande, Assistant in Pathology, Massachusetts General Hospital
    • Dr. Lee Ellis, Professor of Cancer Biology and Professor of Surgery, M.D. Anderson Cancer Center
    • Dr. Stephen Friend, Executive Vice President and Head of Oncology, Merck
    • Dr. Joseph Ippolito, M.D./Ph.D. candidate, Washington University in St. Louis
    • Dr. Seung Kim, Associate Professor in Developmental Biology, Stanford University
    • Dr. Matthew Kulke, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute
    • Dr. Andrew Leiter, Professor of Medicine, Tufts-NEMC
    • Dr. Robert Mayer, Director of Center for Gastrointestinal Oncology, Dana-Farber Cancer Institute
    • Dr. David McFadden, Massachusetts General Hospital / Dana-Farber Cancer Institute
    • Dr. Matthew Meyerson, Director of Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Associate Member, Broad Institute
    • Dr. Marsha Moses, Associate Professor, Children's Hospital Boston
    • Dr. Tan Nguyen, FDA Office of Orphan Products Development
    • Dr. Anil Rustgi, Chief of Gastroenterology Division and Director of Digestive & Liver Center, University of Pennsylvania
    • Dr. Ramesh Shivdasani, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute
    • Dr. Evan Vosburgh, Vice President of Research and Administration, The Verto Institute
    • Dr. Bruce Zetter, Charles Nowiszewski Professor of Cancer Biology, Children's Hospital Boston

Results

Our 2006 CFCF Research Symposium validated our Research Road Map as the best path to discover a cure for carcinoid.

Our 2006 CFCF Research Symposium also identified 3 research priorities to guide our Research Action Plan:

Increase Basic Knowledge

  • This research priority is to understand how carcinoid arises, how carcinoid grows, and how carcinoid metastasizes.  This basic knowledge is critical so that we can "turn off" the molecular mechanisms underlying carcinoid.
  • Increasing our basic knowledge will require performing highly sophisticated research that includes:
    • Identifying the cell of origin for carcinoid
    • Mapping how this cell of origin turns into carcinoid
    • Unlocking the drivers of carcinoid growth and metastasis
    • Figuring out why carcinoid follows a relatively indolent course
    • Leveraging these natural "brakes" in new carcinoid therapies
    • Creating both genomic and proteomic profiles of carcinoid
    • Isolating the multiple disease sub-types of carcinoid

Accelerate Targeted Therapies

  • This research priority is to accelerate the development of new targeted therapies for carcinoid.  Today, carcinoid patients have few therapy options because new drugs are developed for large-population cancers such as lung and breast.  As a rare cancer, carcinoid is typically "last in line."
  • Accelerating targeted therapies will require a highly innovative, collaborative approach to drug development that includes:
    • Validating molecular pathways involved in carcinoid
    • Screening libraries of compounds against promising targets
    • Creating a clinical trial consortium across multiple sites
    • Identifying "responder" and "non-responder" sub-populations
    • Publicly disclosing clinical trial results as quickly as possible

Discover Biomarkers

  • This research priority is to predict when carcinoid will occur, prognosticate its course, and measure its endpoints.  Currently, we lack such predictive, prognostic, and endpoint biomarkers.  As a result, diagnosis comes too late, treatments are not individualized, and outcomes are not accurately measured.
  • Discovering biomarkers will require large-scale, systematic collection and analysis of patient data that includes:
    • Fresh-frozen tumor samples
    • Paraffin-block tumor samples
    • Blood samples
    • Urine samples
    • Demographic profiles
    • Treatment histories
    • Longitudinal responses
    • Clinical outcomes

A special thank you to Dr. Stephen Friend and Dr. Ramesh Shivdasani for co-facilitating the discussion.

We are grateful to all our participants.  Everyone made significant contributions toward curing carcinoid.

 

Get the facts on pancreatic neuroendocrine cancer

Make a Difference Get Involved Today

Sign-up for our e-Newsletter.

Connect with CFCF online:
FacebookTwitterYouTube

Seal Exchange